BioNTech SE American Depositary Share (BNTX)

Price$88.08

Value ScoreC

Growth ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-22.54%

Price vs S&P 500 (4W)-6.41%

VGM Score46.28

Market Capitalization$26.20B

All Metrics

P/CF (Annual)43.12x

Book Value / Share (Quarterly)$85.51

P/TBV (Annual)1.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-45.07%

Cash Flow / Share (Quarterly)$2.77

Payout Ratio (TTM)17.60%

Price vs S&P 500 (YTD)-15.64%

Gross Margin (TTM)82.18%

Net Profit Margin (TTM)-34.02%

EPS (TTM)$-5.86

10-Day Avg Trading Volume0.97M

EPS Excl Extra (TTM)$-5.86

Revenue Growth (5Y)42.88%

EPS (Annual)$-5.44

Dividend / Share (Annual)$0.00

ROI (Annual)-5.83%

Gross Margin (Annual)84.37%

Net Profit Margin (5Y Avg)13.87%

Cash / Share (Quarterly)$66.95

Revenue Growth QoQ (YoY)-23.75%

ROA (Last FY)-5.17%

Revenue Growth TTM (YoY)-11.81%

EBITD / Share (TTM)$-5.14

ROE (5Y Avg)25.77%

Operating Margin (TTM)-41.18%

Cash Flow / Share (Annual)$-1.35

P/B Ratio1.05x

P/B Ratio (Quarterly)1.04x

Net Income / Employee (Annual)$-168,270

EV / Revenue (TTM)3.94x

Net Interest Coverage (TTM)-1.43x

ROA (TTM)-5.82%

EV / EBITDA (TTM)12.29x

EPS Incl Extra (Annual)$-5.44

Current Ratio (Annual)7.54x

Quick Ratio (Quarterly)8.74x

3-Month Avg Trading Volume1.05M

52-Week Price Return-20.04%

EV / Free Cash Flow (Annual)0.88x

Revenue / Employee (TTM)$376,901

Tangible BV / Share (Quarterly)$78.44

P/S Ratio (Annual)6.85x

Asset Turnover (Annual)0.13x

52-Week High$124.00

Operating Margin (5Y Avg)14.98%

EPS Excl Extra (Annual)$-5.44

CapEx CAGR (5Y)54.53%

Tangible BV CAGR (5Y)69.43%

26-Week Price Return-14.61%

Quick Ratio (Annual)7.49x

13-Week Price Return-13.60%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)8.80x

Enterprise Value$11.59B

Revenue / Share Growth (5Y)44.19%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)68.27%

Revenue / Employee (Annual)$425,127

Inventory Turnover (Annual)2.28x

Pretax Margin (Annual)-36.61%

Cash / Share (Annual)$68.46

3-Month Return Std Dev52.96%

Gross Margin (5Y Avg)84.18%

Net Income / Employee (TTM)$-185,502

ROE (Last FY)-5.91%

Net Interest Coverage (Annual)12.06x

EPS Basic Excl Extra (Annual)$-5.44

P/FCF (TTM)17.78x

Receivables Turnover (TTM)3.36x

EV / Free Cash Flow (TTM)16.54x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-5.86

Receivables Turnover (Annual)2.39x

ROI (TTM)-6.59%

P/S Ratio (TTM)7.73x

Pretax Margin (5Y Avg)24.79%

Revenue / Share (Annual)$13.73

Tangible BV / Share (Annual)$81.07

Price vs S&P 500 (52W)-44.40%

Year-to-Date Return-7.48%

5-Day Price Return-3.95%

EPS Normalized (Annual)$-5.44

ROA (5Y Avg)20.29%

Net Profit Margin (Annual)-39.59%

Month-to-Date Return-8.20%

Cash Flow / Share (TTM)$15.04

EBITD / Share (Annual)$-4.89

Operating Margin (Annual)-48.97%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)24.10x

ROI (5Y Avg)25.26%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-5.86

P/TBV (Quarterly)1.14x

Payout Ratio (Annual)5.13%

P/B Ratio (Annual)1.03x

Inventory Turnover (TTM)2.81x

Pretax Margin (TTM)-30.29%

Book Value / Share (Annual)$88.46

Price vs S&P 500 (13W)-21.86%

Beta1.30x

P/FCF (Annual)4.21x

Revenue / Share (TTM)$11.62

ROE (TTM)-6.69%

52-Week Low$79.52

vGradeC

gGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-2.43est. -2.62

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.07

4.00

4.04

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00
HALOHalozyme Therapeutics, Inc.	C	B	B	$71.53

About

BioNTech is a German biotechnology company developing mRNA-based cancer immunotherapies and vaccines for infectious diseases. Its oncology pipeline includes multiple therapeutic modalities such as mRNA drugs, cell therapies, bispecific antibodies, and antibody-drug conjugates. The company's first commercialized product is Comirnaty, a COVID-19 vaccine developed in partnership with Pfizer.